Anyone heard of phendimetrazine?????

[Camri]

Had any experience with this or know of a site that educates the comparison of this with phentermine?

[soccerwoman]

Camri,

Phendimetrazine is also known as Bontril. Some Physicians prescribe Bontril with Phen, the FDA has issued a WARNING against this practice.

From what I could see researching Phendimetrazine using www.google.com, it is cheaper than Phentermine, but considered slightly less effective by some web sites. I will post some of the web sites I found at the bottom.

From the FDA web site:
http://www.fda.gov/medwatch/safety/1998/plegin.htm

Wyeth-Ayerst (maker of Phendimetrazine) has received information concerning patients who had taken phendimetrazine and experienced valvular abnormalities and/or primary pulmonary hypertension. It appears that all patients had a history of using at least one other anorexigen (other diet drugs)

Phendimetrazine is not indicated for concomitant use with any other anorexigenic drug. Wyeth-Ayerst does not recommend such concomitant use and does not know of any adequate and well-controlled studies demonstrating the safety and effectiveness of these drugs when used in combination.
Phendimetrazine is not indicated for long-term use. The labeling clearly states that it is indicated only for short-term use of a few weeks.

I can NOT vouch for the validity of the claims of the below mentioned web site, but it did have some information. http://www.xenical-vs-phen*********vs...iet_pills.html

[ February 21, 2002: Message edited by: soccerwoman ]

[Heavensent]

Wow that is interesting to read. My doctor has giving me both pills to take. I take 30mg of Phentermine in the morning and 35 of the phendimetrazine in the afternoon. Does anyone else do this??

[RondaL5272]

Hi, my dr just put me on the same because I was still having cravings. So far I feel pretty good and the cravings are gone.

Ronda

SW 176 01/02
CW 154
gw 135

[Camri]

Thanks soccerwoman for that information! Answered all of my questions and I am going to take time to research the links you sent! You guys that are taking this keep in touch and up to date on your experience and hopefully lots of success!

[nal]

Okay - those of you who have been here for awhile will know where this came from. I hope I have copied this information correctly. Soccermom, you did very well - there are a couple of corrections to the info on the website you cited. I have spent a half an hour cutting and pasting - I apologize if I goofed in anyway. I've done my best. Disclaimer: I do not in any way pretend to be an expert in this subject.

Phendimetrazine comes in 35mg immediate release tablets & capsules & 105 mg slow release capsules.

Bontril PDM® is a 35 mg tablet. Bontril-SR® is a 105mg Slow Release capsule.

Amarin Pharma manufactures Bontril. That other website says Carnrick Labs. That other website lists a bunch of errors under, “Bontril-SR Disclosures / Information Page.” The info they list is general copied info from 50 million other sites about all the anorectic drugs. The info they list is not specifically for phendimetrazine or Bontril!



Plegine® was a 35mg tablet. This tablet was manufactured by Wyeth-Ayerst. It has been withdrawn from the market.

Wyeth-Ayerst made Pondimin®. Shortly after Wyeth-Ayerst withdrew Pondimin from the market, they withdrew Plegine. Hmmmmmm … I wonder why??? Notice how they don’t mention that they were the maker of Pondimin in that FDA letter?



That other website list this, “US FDA Class 4 Medication” under Bontril-SR®. This is wrong!!!

Bontril is an FDA Schedule C-III controlled substance.



Phendimetrazine or Bontril should not be considered less effective than phentermine.

Doctors usually prescribe the Bontril PDM® or phendimetrazine 35mg (not the Bontril-SR® like the other website talks about) with phentermine.

Soccermom said – “Phendimetrazine is also known as Bontril. Some Physicians prescribe Bontril with Phen, the FDA has issued a WARNING against this practice.”

The FDA has not issued a warning against this practice. This is known as “off-label” prescribing and doctors are allowed to do this.

The same thing could be said about prescribing phentermine with Prozac.



Here is the famous “Dear Doctor” letter that was sent out by Medeva after the big fen/phen ordeal …





Dear Doctor or Health Care Professional:



The recent actions taken by Wyeth-Ayerst to withdraw their weight loss medications, Pondimin (fenfluramine hydrochloride) Tablets C-IV and Redux (dexfenfluramine hydrochloride) Capsules C-IV from the market have raised numerous questions and concerns about the status of other medications indicated in the treatment of exogenous obesity. Medeva Pharmaceuticals, Inc. would like to provide the medical community with important information about our product, IONAMIN (phentermine resin) Capsules C-IV.



This voluntary market withdrawal decision does NOT affect the availability of IONAMIN Capsules.



The decision to withdraw Pondimin and Redux was based on emerging information regarding significant adverse effects associated with these products. This information concerned abnormal heart valve findings which were determined to present an unacceptable risk to patients. The cases of valvular heart disease have reportedly involved patients taking fenfluramine in combination with phentermine; fenfluramine alone; dexfenfluramine alone; or dexfenfluramine in combination with phentermine. There have been no reported cases to date of this valvular condition occurring with the use of phentermine alone.



Primary pulmonary hypertension (PPH) is another significant adverse effect which has been reported to occur with increased frequency in patient using certain appetite suppressants (mainly fenfluramine or dexfenfluramine)1. Medeva is aware of only a few isolated case reports of PPH possibly associated with phentermine monotherapy over the last 38 years. Although present data do not support an association between PPH and phentermine monotherapy, the possibility cannot be ruled out.



For patients with a history of fenfluramine or dexfenfluramine use, alone or in combination with phentermine, a thorough cardiac evaluation may be appropriate prior to embarking on a new therapeutic regimen for the treatment of obesity. The safety and efficacy of IONAMIN Capsules in patients with existing valvular dysfunction and/or heart murmur, in whom the influence of increased sympathomimetic activity may be undesirable, have not been established, and its use in such patients cannot be recommended.



IONAMIN (phentermine resin) Capsules C-IV are indicated in the management of exogenous obesity as a short-term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. In addition to dietary adjustments, comprehensive weight loss programs also include behavioral modifications and increased physical activity, at a sufficient level to produce health benefits toward the improvement of obesity-related medical conditions.



IONAMIN Capsules are indicated as monotherapy only. There are no data to support the safety and/or efficacy of combination therapy with phentermine and any other drug products for the treatment of obesity, including serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, paroxetine). The coadministration of these agents is not recommended.



At the present time, the long-term safety and efficacy of IONAMIN Capsules have not been systematically evaluated, and long-term use of IONAMIN Capsules is not recommended.



Use of pharmacotherapy for weight loss should not be instituted for cosmetic purposes, but rather, should be reserved for those individuals with a body mass index (BMI) of greater than or equal to 30 kg/m2, or for those with a BMI or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., hypertension, diabetes, hyperlipidemia), in whom non-pharmacologic interventions have been unsuccessful.



Further information regarding the withdrawal of Pondimin and Redux and valvular heart disease can be obtained from the FDA's Internet Website at http://www.fda.gov/cder/news/fenphenqa2.htm. If you would like additional information about IONAMIN Capsules, the only phentermine resin product available, please contact Medeva's Medical Services Department at (800) 234-5535.



Sincerely,



Terrance C. Coyne, M.D.

Vice President, Medical Affairs





Phendimetrazine
Bontril®, Plegine® | Adipost® | Bock-Arate™ | Bontril® | Bontril® PDM | Cam-Metrazine™ | Kraft-Pleg™ | Kraft-Stat 35™ | Melfiat® | Obezine® | Phenazine® | Phendiet™ | Phenzene™ | Plegine® | Prelu-2® | Rapdone™ | Spec-Tabs™ | Statobex™ | X-Trozine® LA

Classification:

• Adrenergic agonists
• Autonomic Agents
• Psychostimulants
• Psychotropic Agents
• Sympathomimetics


--------------------------------------------------------------------------------

Indications:

•obesity


--------------------------------------------------------------------------------

Comments:

NOTE: Phendimetratizine is a schedule C-III controlled substance.

Description: Phendimetrazine is an oral, indirect-acting, nonamphetamine sympathomimetic amine. It is used as an anoretic agent for short-term (8 to 12 weeks) adjunct in the treatment of exogenous obesity. Phendimetrazine is only indicated for use as monotherapy only. This class of agents has a high potential for abuse and addiction. This drug was approved by the FDA in 1961.
Mechanism of Action: Appetite-suppression activity is believed to occur through direct stimulation of the satiety center in the hypothalamic and limbic region.
Contraindications/Precautions: Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of alcoholism or drug abuse, during or within 14 days of administration of an MAO inhibitor.
Children: Safety and efficacy have not been established in children.
Combination antiobesity therapy: Concurrent use of phendimetrazine with other anorectic agents is contraindicated. Phendimetrazine is not recommended for patients who used any anorectic agent within the prior year.
Pulmonary hypertension: In a case-control epidemiological study, the use of anorectic agents, including phendimetrazone, was associated with an increased risk of developing pulmonary hypertension, a rare, but often fatal disorder. The use of anorectic agents for longer than 3 months was associated with a 23-fold increase in the risk of developing pulmonary hypertension. Increased risk of pulmonary hypertension with repeated courses of therapy cannot be excluded. The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension. Under these circumstances, phendimetrazone should be immediately discontinued, and the patient should be evaluated for the possible presence of pulmonary hypertension.
Valvulopathy: Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine has been reported. Possible contributing factors include use for extended periods of time, higher than recommended dose, and/or use in combination with other anorectic drugs. Valvulopathy has not been reported with phendimetrazone monotherapy. The potential risk of possible serious adverse effects such as valvular heart disease and pulmonary hypertension should be assessed carefully against the potential benefit of weight loss. Baseline cardiac evaluation should be considered to detect preexisting valvular heart diseases or pulmonary hypertension prior to initiation of phendimetrazone treatment. Phendimetrazone is not recommended in patients with known heart murmur or valvular heart disease. Echocardiogram during and after treatment could be useful for detecting any valvular disorders which may occur.
Drug Interactions:
Guanethidine: Anorexiants can decrease the antihypertensive effect of guanethidine.
Monoamine oxidase inhibitors: Can increase the pressor response to anorexiants. Do not administer phendimetrazine within 14 days of an MAOI drug.
Tricyclic antidepressants: Can decrease the effects of anorexiants.
Adverse Reactions: Anorexigens have been reported to be associated with the occurrence of serious regurgitant cardiac valvular disease, including disease of the mitral, aortic, and/or tricuspid valves. Primary pulmonary hypertension (PPH), a rare, frequently fatal disease of the lungs, has also been found to occur with increased frequency in patients receiving anorexigens. There have been reports of PPH and valvular irregularities in patients receiving phendimetrazine, all of which had a history of using at least one other anorexigen. No case of valvulopathy has been reported when phendimetrazine was used alone. Other adverse reactions that may occur with phendimetrazine include nausea/vomiting, diarrhea, sinus tachycardia, hypertension, overstimulation, restlessness, dizziness, insomnia, dyskinesia, euphoria, dysphoria, xerostomia, mydriasis, ocular irritation, blurred vision, anorexia, weight loss, impotence.
Available as:
Capsules or Tablets
phendimetrazine 35 mg
Available generically.
Extended-release Capsules or Tablets
phendimetrazine 105 mg
Available generically.
Dosage:
NOTE: The safety and effectiveness of the combined use of phendimetrazine with other anorexigens in the treatment of obesity have not been established, and there is no approved use of these products together in the treatment of obesity. Phendimetrazine is approved only as a single agent for short-term use (i.e., a few weeks).
For the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone:
Oral dosage:
Adults: 35 mg PO 2—3 times per day, 1 hour before meals.
NOTE: To limit unwarranted exposure and risks, treatment with phendimetrazine should be continued only if the patient has satisfactory weight loss within the first 4 weeks of treatment (e.g., weight loss of at least 4 lbs, or as determined by the physician and patient).

[ Revised 8/25/99 ]

PDR® entry for
Bontril Slow-Release Capsules (Amarin)

DESCRIPTION
Phendimetrazine tartrate, as the dextro isomer, has the chemical name of (+)-3,4-Dimethyl-2-phenylmorpholine Tartrate.
The structural formula is as follows:

Phendimetrazine tartrate is a white, odorless powder with a bitter taste. It is soluble in water, methanol and ethanol.
Bontril Slow-Release capsules contain FD&C Yellow No. 6 as a color additive.
ACTIONS
Phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics". It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions or metabolic effects may be involved.
Adult obese subjects instructed in dietary management and treated with anorectic drugs lose more weight on the average than those treated with placebo and diet, as determined in relatively short term clinical trials.
The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origin of the increased weight loss due to the various drug effects is not established. The amount of weight loss associated with the use of an anorectic drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drug prescribed, such as the physician investigator, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.
The natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.
The active drug 105 mg of phendimetrazine tartrate in each capsule of this special slow-release dosage form approximates the action of three 35 mg non-time release doses taken at 4 hours intervals.
The major route of elimination is via the kidneys where most of the drug and metabolites are excreted. Some of the drug is metabolized to phenmetrazine and also phendimetrazine-N-oxide.
The average half-life of elimination when studied under controlled conditions is about 1.9 hours for the non-time and 9.8 hours for the slow-release dosage form. The absorption half-life of the drug from conventional non-time 35 mg phendimetrazine tartrate tablets is approximately the same. These data indicate that the slow-release product has a similar onset of action to the conventional non-time-release product and, in addition, has a prolonged therapeutic effect.
INDICATIONS
Phendimetrazine tartrate is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see ACTIONS ) should be measured against possible risk factors inherent in their use such as those described below.
CONTRAINDICATIONS
Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate and severe hypertension, hyperthyroidism, known hypersensitivity, or idiosyncrasy to the sympathomimetic amines, glaucoma. Agitated states. Patients with a history of drug abuse. Use in patients taking other CNS stimulants including monoamine oxidase inhibitors.
WARNINGS
Tolerance to the anorectic effect usually develops within a few weeks. When this occurs, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.
Use of phendimetrazine tartrate within 14 days following the administration of monoamine oxidase inhibitors may result in a hypertensive crisis.
Abrupt cessation of administration following prolonged high dosage results in extreme fatigue and depression. Because of the effect on the central nervous system phendimetrazine tartrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.
PRECAUTIONS
Caution is to be exercised in prescribing phendimetrazine tartrate for patients with even mild hypertension.
Insulin requirements in diabetes mellitus may be altered in association with the use of phendimetrazine tartrate and the concomitant dietary regimen.
Phendimetrazine tartrate may decrease the hypotensive effect of guanethidine.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
Usage in Pregnancy: Safe use in pregnancy has not been established. Until more information is available, phendimetrazine tartrate should not be taken by women who are or may become pregnant unless, in the opinion of the physician, the potential benefits outweigh the possible hazards.
Usage in Children: Phendimetrazine tartrate is not recommended for use in children under 12 years of age.
ADVERSE REACTIONS
Cardiovascular: Palpitation, tachycardia, elevation of blood pressure.
Central Nervous System: Overstimulation, restlessness, dizziness, insomnia, tremor, headache; rarely psychotic episodes at recommended doses, agitation, flushing, sweating, blurring of vision.
Gastrointestinal: Dryness of the mouth, diarrhea, constipation, nausea, stomach pain.
Genitourinary: Changes in libido, urinary frequency, dysuria.
DRUG ABUSE AND DEPENDENCE
Controlled Substance: Phendimetrazine tartrate is a Schedule III controlled substance.
Dependence: Phendimetrazine Tartrate is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of phendimetrazine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.
OVERDOSAGE
Manifestations of acute overdosage may include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states.
Fatigue and depression usually follow the central stimulation.
Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Poisoning may result in convulsions, coma, and death.
Management of acute intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard.
Acidification of the urine increases phendimetrazine tartrate excretion.
Intravenous phentolamine (Regitine) has been suggested for possible acute, severe hypertension, if this complicates overdosage.
DOSAGE AND ADMINISTRATION
One Slow-Release Capsule (105 mg) in the morning, taken 30-60 minutes before the morning meal.
Phendimetrazine Tartrate is not recommended for use in children under twelve years of age.
HOW SUPPLIED
Phendimetrazine Tartrate Slow-Release Capsules, 105 mg is supplied in bottles of 100 opaque green and clear yellow capsules, imprinted with the letter "A" and 047. NDC # 65234-047-10.
Store at controlled room temperature, 15°- 30°C(59°-86°F).
CAUTION
** only
Manufactured for Amarin Pharmaceuticals Inc.

PHEEEEEEEEW!! I'm exhausted! Gosh I hope I did this right.

[ February 22, 2002: Message edited by: nal ]

[ February 22, 2002: Message edited by: nal ]

[Camri]

NAL- I POSTED TO YOUR - OFF TOPIC -AND GAVE YOU MY ADDRESS I AM NEW TO THIS FORUM OR ANY FORUM FOR THAT MATTER - BUT I HAVE ENJOYED READING AS MANY OF YOUR POST AS I CAN FIND -LIKE I SAID BEFORE YOU SEEM TO KNOW YOUR STUFF OR KNOW WHERE TO FIND IT -A COUPLE OF QUESTIONS IN OTHER POST IS LIMITED IT SEEMS ON THIS FORUM - LIKE FOR EXAMPLE HOW DO I KNOW IF THE PHEN I ORDER WILL HAVE BLUE SPECS DOES IT DEPEND ON WHERE I ORDER IT FROM - JUST WANTED TO TAP YOUR KNOWLEDGE
THANKS SO MUCH! I ALSO AM INTERESTED IN YOUR EXPERIENCE AND WHAT YOU ARE CURRENTLY WORKING TOWARDS-
CAMRI

[LBos236]

My doctor put me on the same thing. 30 mg of phentermine and 35 mg of phendimetrazine. When I asked why 2 different pills, she said that the phendimetrazine was the afternoon/early evening pill and it won't keep me up all night. I don't know if this is accurate, but it's what she told me.

[soccerwoman]

Hi Nal,

I respectfully disagree, the information about the warning came from the FDA web site. I trust the FDA website.

You stated that it is the same as taking
Phen Pro. Yes, doctors are "allowed" to do this. However in this case the manufacturer recommends against it do to findings in studies. So it isn't the same thing, is it?
http://www.fda.gov/medwatch/safety/1998/plegin.htm

In fact here it is again:

WARNING regarding Valvular Irregularities and Primary Pulmonary Hypertension


If you have any heart problems while taking both of these drugs together, please consult your doctor.

[nal]

I cannot take credit for finding this information. I have indicated before that I have a "source" of information. I think most of you know who it is. I hesitate to mention names for fear of having the info deleted from the site.

I will check back regarding your comment, S.W. I've read the warning, and it seems to be primarily aimed at fen/phen. These things are so confusing. If you look on the web, you can find information to support just about anything. So much conflicting information. I'm never sure which info to believe.

I'll get back to you.

[ February 22, 2002: Message edited by: nal ]

[soccerwoman]

Hi Nal,

You are right, the FDA does specifically mention Phen with Fen.
It was the below message that caught my attention:

"there have been reports that physicians are prescribing phendimetrazine in combination with phentermine in a limited number of cases. We emphasize that such concomitant use is not indicated."

I can see Phen with Prozac or Effexor, they do different things. But Phen with Phendimetrazine? Seems like stimulant overkill to me.

But I am not a doctor, I just play one on the internet.

[nal]

Soccermom - here is an answer from my source. Please don't misinterpret this as my trying to argue with you. I am merely a messenger.

“Yes, the info did come off the FDA site, but this is just a letter from Wyeth-Ayerst that the FDA posted. This is not the FDA saying anything. This is just the FDA posting the Wyeth-Ayerst letter on their (FDA) website.



We didn’t state, “… it is the same as taking Phen Pro.”



We said, “The same thing could be said about prescribing phentermine with Prozac.”



What we did is compare the Ionamin letter to the Plegine letter:



Both of these letters were posted on the FDA site.



Both of these letters were written by the manufactures

(Wyeth-Ayerst for Plegine & Mediva for Ionamin).



Both manufactures had comments about concomitant use/coadministration/monotherapy …



Wyeth-Ayerst stated –



“The safety and effectiveness of the combined use of Plegine with other anorexigens in the treatment of obesity have not been established, and there is no approved use of these products together in the treatment of obesity. Plegine is approved only as a single agent for short-term use (i.e., a few weeks).”



“Phendimetrazine is not indicated for concomitant use with any other anorexigenic drug. Wyeth-Ayerst does not recommend such concomitant use and does not know of any adequate and well-controlled studies demonstrating the safety and effectiveness of these drugs when used in combination.”





Mediva stated –



“IONAMIN Capsules are indicated as monotherapy only. There are no data to support the safety and/or efficacy of combination therapy with phentermine and any other drug products for the treatment of obesity, including serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, paroxetine). The coadministration of these agents is not recommended.





Both manufacturers had something to say about long-term use …



“Phendimetrazine is not indicated for long-term use. The labeling clearly states that it is indicated only for short-term use of a few weeks.”



“At the present time, the long-term safety and efficacy of IONAMIN Capsules have not been systematically evaluated, and long-term use of IONAMIN Capsules is not recommended”.





Both manufactures had reports or were aware of their drugs being connected to a side-effect/adverse reaction …



Wyeth-Ayerst stated, “There have been reports of PPH and valvular irregularities in users of Plegine (phendimetrazine tartrate tablets).



Mediva stated, “Medeva is aware of only a few isolated case reports of PPH possibly associated with phentermine monotherapy over the last 38 years.”





In both cases the manufacturers recommend against it due to findings in studies or from some source!





In fact here it is again:



“The safety and efficacy of IONAMIN Capsules in patients with existing valvular dysfunction and/or heart murmur, in whom the influence of increased sympathomimetic activity may be undesirable, have not been established, and its use in such patients cannot be recommended.”

[Blippo]

bump

[ifonlyiwasskinny]

I just got this email about that medicine: plz read.....

All drugs containing PHENYLPROPANOLAMINE are being recalled. You may want to try calling the 800 number listed on most drug boxes and inquire about a REFUND. Please read this CAREFULLY. Also, please pass this on to everyone you know. STOP TAKING anything containing this ingredient. It has been linked to
increased hemorrhagic stroke (bleeding in the brain) among women ages
18-49 in the three days
after starting use of medication. Problems were not found in men, however,
the FDA
recommended that everyone (even children) seek an alternative medicine.

The following medications contain Phenylpropanolamine:

Acutrim Diet Gum Appetite Suppressant
Acutrim Plus Dietary Supplements
Acu trim Maximum Strength Appetite Control
Alka-Seltzer Plus Children's Cold Medicine

Effervescent

Alka-Seltzer Plus Cold medicine (cherry or orange)

Alka-Seltzer Plus Cold Medicine Original

Alka-Seltzer Plus Cold & Cough Medicine
Alka-Seltzer Plus Cold & Flu Medicine
Alka-Seltzer Plus Cold & Sinus Effervescent
Alka Seltzer Plus Night-Time Cold Medicine
BC Allergy Sinus Cold Powder
BC Sinus Cold Powder
Comtrex Flu Therapy & Fever Relief
Day &Night Contac 12-Hour Cold Capsules
Contac 12 Hour Caplets
Coricidin D Cold, Flu & Sinus
Dexatrim Caffeine Free
Dexatrim Extended Duration
Dexatrim Gelcaps
Dexatrim Vitamin C/Caffeine Free
Dimetapp Cold & Allergy Chewable Tablets
Dimetapp Cold & Cough Liqui-Gels
Dimetapp DM Cold & Cough Elixir
Dimetapp Elixir
Dimetapp 4 Hour Liquid Gels
Dimetapp 4 Hour Tablets
Dimetapp 12 Hour Extentabs Tablets
Naldecon DX Pediatric Drops
Permathene Mega-16
Robitussin CF
Tavist-D 12 Hour Relief of Sinus & Nasal Congestion
Triaminic DM Cough Relief
Triaminic Expectorant Ches t & Head
Triaminic Syrup Cold & Allergy
Triaminic Triaminicol Cold & Cough

I just found out and called the 800# on the container for Triaminic and
they informed me that they are voluntarily recalling the following
medicines because of a certain ingredient that is causing strokes and
seizures in children:

Orange 3D Cold &Allergy Cherry (Pink)
3D Cold &Cough Berry
3D Cough Relief Yellow 3D Expectorant

They are asking you to call them at 800-548-3708 with the lot number on
the box so they can send you postage for you to send it back to them, and
they will also issue
you a refund.

If you know of anyone else with small children, PLEASE PASS THIS ON. THIS
IS SERIOUS STUFF!

DO PASS THIS ALONG TO ALL ON YOUR MAILING LIST so people are informed.
They can then pass it along to their families.

To confirm these findings please take time to check the following:

URL: Phenylpropanolamine Information Page

http://www.fda.gov/cder/drug/infopage/ppa/default.htm

[ifonlyiwasskinny]

DUH ON ME

DIFFERENT NAMES

THOUGHT THEY WERE THE SAME....

Sorry DUH...... sometimes I'm alittle slow lol

[Paulokc]

I take Phendimetrazine 35mg and I have been having trouble sleeping. Has anyone else had this same problem?

[inthestars]

I also had insomnia with phentermine. It's a side effect. Have you tried to take melatonin to help you get some sleep?

[Ilijah]

Hello!
I just started on Phen-D (my shorthand for Phendimetrazine) and I was wondering about the MD prescribing both Phen-T (my shorthand for Phentermine)...I had been on Phen-T in the past and lost weight...but when I went back on it this year...did not seem as effective. Started the Phen-D (catching on?) this morning and can say that I felt decrease in appetite and I honestly think that I will be able to fall asleep tonight, unlike when I was taking Phen-T. I am not going through an MD's office and I had an opportunity to talk w/ other patients and for the most part (even the MD stated this) that the Phen-D is for short term (1-2 weeks) and then he will change to another medication, but it seems like most people are on Phen-D for longer than 1-2 weeks. Is that the case?

[nina_in408]

The clinic i go to gives both out, either phentermine or phendimetrazine. Phendimetrazine 30 mg is taken 3x a day before meals. phentermine 37.5 mg once a day in the morning. Phendimetrazine is more expensive because there are more pills. From my experience, phentermine works better and it feels like it is stronger. The doctor gave me both. I start off by taking phentermine in the morning and on some days maybe 6 or 7 times a month before my period when i feel more tired and hungry and take 1 phendimetrazine around lunch. Taking both really kills your appetite. However i dont do that on a daily.

[benson012094]

[tlc93]

test

[tlc93]

wow sorry guys way to big!

[tlc93]

?

[Shadley]

Im so confused!!!!! Everyone's doctors tell them different things. My dr. prescribed 2-3 Phendimetrazine first thing in the morning when I wake up, which is 5:30. And then at either 10 or 12 take 1/2 or 1 Phentermine. I'm going back to see him tomorrow because everyone is saying different things and I want to know EXACTLY what to do.

[nynavae]

That's the thing about doctors, they all have their own ideas about how to treat patients. There is no exact formula. And what works for me might not be the best thing for you, etc. I would do what the doctor says and see how that works for starters.

[beyond_driven]

Bontril didn't do anything for me except make me extremely gassy, hot, and ill.

[BabySteps813]

MY DX HAS PRESCRIBED ME PHEN-D, 2 AT BREAKFAST, 2 AT LUNCH, AND 2 AT DINNER AND IT WORKS VERY WELL FOR ME. I AM NOT HUNGRY....... IN FACT I HAVE TO FORCE MYSELF TO EAT... AND I'VE LOST 11 POUNDS IN FOUR DAYS. I'M SURE SOME OF THAT IS WATER WEIGHT, BUT I THINK THATS A PRETTY GOOD START.

FOR THE PERSON HAVING DIFFICULTY SLEEPING DRINK SOME SLEEPYTIME HERBAL TEA OR TAKE 1 TYLENOL PM ABOUT 3 HOURS BEFORE YOU WANT TO GO TO BED FOR A COUPLE OF DAYS UNTIL YOUR BODY GETS USED TO IT. USUALLY THE SLEEPYTIME TEA WORKS FOR ME. I HAVE A CUP ABOUT A HOUR BEFORE I WANT TO GO TO BED AND I'M ABLE TO SLEEP THROUGH THE NIGHT W/O ANY SLEEP DISTURBANCE OR AFTER EFFECTS IN THE MORNING.

GOOD LUCK!

[X-Quisite]

From what I understand, if you take Phentermine + 10-20 mg of prozac it helps take away the side effect of not sleeping and irritability. Any more than the 20mg of prozac actually stops the phentermine from working! I was using both, finally cut back to 20mg and have started losing! YAE!! I also take a water pill each day.

I had a Dr tell me the other day that even Phen Fen wasn't so bad because they are still using it in Europe. (After I had my cardio check-up from worries over taking the Phen Fen years ago)

[mipoo670]

I need to locate info on phendimetrazine tartrate 35 mg. small blue pill. one side has a crescent half moon shaped symbol, other side has numbers 35. Any help is appreciated!

[Ladybug0872]

I use phen-d, but it's a 35mg yellow pill. No wonder the others on the board thought my dosage was bizarre. I am prescribed 2 pills 3x/day, 1 hour before meals, but I only take about 4 a day so I can sleep at night. I haven't seen any blue pills. I'll look in my PDR tonight, and get back to you tomorrow.

[mipoo670]

Thanks ladybug!

[AngieDee123]

My pills are green on one side and yellow on the other. on the green side there is a b and 35. So I guess it is 35mg

[scatanafas]

this board ****s...noone ever posts here...does that mean that not too many people take phend?

Hi Scantanafas I take phen-d!!! What's going on???

[jaysma]

I'm taking Phen-D too & I agree, this board doesn't have enough action!